Close Menu

Luminex's recent decision to reduce its workforce by 5 percent, close an office in Australia, and seek a buyer for its newborn screening business, was in part influenced by its attempt to obtain US regulatory clearance for its NeoPlex4 test, according to the firm's CEO.

Luminex's NeoPlex4 assay is based on the firm's xMAP bead array technology and tests for four analytes related to congenital hypothyroidism, congenital adrenal hyperplasia, and cystic fibrosis.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Bloomberg reports that the DNA-for-cash deal reported in Kentucky might be a more widespread scam.

St. Jude Children's Research Hospital scientists have treated infants with X-linked severe combined immunodeficiency using gene therapy in an early phase study.

St. Louis Public Radio reports that some African Americans are turning to DNA ancestry testing to help guide genealogical searches.

In Nature this week: a genomic analysis of the snailfish Pseudoliparis swirei, ancient DNA analysis gives insight into the introduction of farming to England, and more.

May
15
Sponsored by
Thermo Fisher Scientific

This webinar will discuss how Radboud University Medical Center’s Department of Human Genetics is using exon-level copy number variant (CNV) detection by microarray to assist its efforts in constitutional genome testing.